Health-related quality-of-life analyses from a multicenter, randomized, double-blind phase 2 study of patients with differentiated thyroid cancer treated with lenvatinib 18 or 24 mg/day

By sjmartinez • March 3, 2023

Taylor MH, Leboulleux S, Panaseykin Y, Konda B, de La Fouchardiere C, Hughes BGM, Gianoukakis AG, Park YJ, Romanov I, Krzyzanowska MK, Garbinsky D, Sherif B, Pan JJ, Binder TA, Sauter N, Xie R, Brose MS. Health-related quality-of-life analyses from a multicenter, randomized, double-blind phase 2 study of patients with differentiated thyroid cancer treated with lenvatinib 18 or 24 mg/day. Cancer Med. 2023 Feb;12(4):4332-4342. doi: 10.1002/cam4.5308. Epub 2022 Dec 4. PMID: 36464853; PMCID: PMC9972135.

Tags: dose intensity, Endocrinology, Harbor UCLA, HRQoL, kinase inhibitor, lenvatinib, Quality of Life, radioiodine-refractory differentiated thyroid cancer

Female Reproduction Across the Life Span

Leung AM. Female Reproduction Across the Life Span. Endocrinol Metab Clin North Am. 2026 Dec;55(4):xiii-xiv. doi: 10.1016/j.ecl.2026.08.014. Epub 2026 Sep 9. PMID: 42907061.

New-Onset Graves’ Disease in the Postpartum Period Initially Suspected to Represent Postpartum Thyroiditis

Sharifi M, Navabi K. New-Onset Graves' Disease in the Postpartum Period Initially Suspected to Represent Postpartum Thyroiditis. Cureus. 2026 Sep 15;18(9):e116275. doi: 10.7759/cureus.116275. PMID: 42890272;[...]

A Single-Cell Atlas of Diabetes-Associated Remodeling in the Human Corneal Limbus

Zha D, Wang Y, Shah R, Ebrahimi SM, Poe AJ, Amador C, Inzalaco J, Fealy A, Sawant OB, Kramerov AA, Wang ZP, Ljubimov AV, Saghizadeh[...]